Drugs / Zebtorizumab
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06758037 Background | Jan 2025 → Dec 2026 expected | diffuse large B-cell lymphoma | First Affiliated Hospital of Ningbo University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zebtorizumab | “All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy.” NCT06758037 ↗ |